Genmab A/S — Biotechnology. Scored on the same transparent model behind the daily rankings.
★
GMAB
Genmab A/S · Biotechnology
FCF$872mC+
Rev+30.7%A
D/E0.94C
P/E21.9xB+
PEG1.02B+
74Score
$28.68$17.6B
1Y Target$37.96Analyst consensus · 10 analysts
5Y Target$55.58Compound horizon
10Y Target$82.45Long-dated conviction
FCF$872mTTM · 03/26C+
FCF $872m — respectable but not differentiating · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+30.7%TTM YoYA
Revenue +30.7% — hypergrowth, top decile
D/E0.94C
D/E 0.94 — more levered than most Healthcare peers (≈90th pctile)
P/E21.9xB+
P/E 21.9 — below the Healthcare median (≈40th pctile)
PEG1.02B+
PEG 1.02 — near fair value, classic Lynch benchmark (1.0)
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 74
Quality0.78
Growth0.98
Value0.53
Why this score
Buying back stock
Durable high returns
Entry · Margin of safety
52-week rangeMid-range
19% off the 12-month high
vs DCF fair value36% belowest. fair value ~$45
What the price assumes: free cash flow compounding at ~4% a year for the next decade — vs the ~25% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability45% · A-gross profit ÷ total assets (Novy-Marx)
ROIC14.4% · B+return on invested capital — not score-weighted
Why now
Biotechnology · market cap $17.6b. 19% off the 52-week high of $35.43. Revenue growing +31% — in hypergrowth territory. 10 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $37.96 (implying +32% upside).
Moat
Net margin 36% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 21% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 106% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $37.96 (10-analyst consensus) — fundamentals + valuation re-rating. 5 yr $55.58 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $82.45 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
GMAB vs the Top Picks average
Pillar
GMAB
Book avg
Diff
Quality
0.78
0.83
-0.05
Growth
0.98
0.91
+0.07
Value
0.53
0.75
-0.22
Averaged across the 30 names in today's Top Picks (mean score 81.8). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · GMAB
Trend
+5.3 over 34 daily scores
From 68.7 (Jun 22) → 74.0 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · GMAB
$
%
%
Shares to buy
69
Position size
$1,979
4.0% of portfolio
Stop price
$21.51
25% below $28.68
$ at risk if stopped
$494.73
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Genmab A/S (GMAB): score, valuation & FAQ
Genmab A/S (GMAB) is a Biotechnology company that scores 74 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A), P/E (B+) and PEG (B+). On valuation, GMAB sits about 36% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 4% annual free-cash-flow growth over the next decade.
Is GMAB a good stock to buy?
Bull Rankings scores GMAB 74 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (A), P/E (B+) and PEG (B+). A score is a quantitative screen of Genmab A/S's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does GMAB score 74 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). GMAB earns its highest marks on Rev (A), P/E (B+) and PEG (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is GMAB overvalued or undervalued?
Based on $28.68, GMAB sits about 36% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 4% annual free-cash-flow growth over the next decade. It trades at a 21.9x× P/E (graded B+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in GMAB?
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.